Why does at-home treatment of agitation matter?<\/p>\n
Teva, citing its own market research, says acute agitation affects 25% to 40% of patients with schizophrenia or bipolar disorder, and that acute treatment options remain limited outside healthcare settings.2<\/p>\n
\u201cAgitation can escalate quickly, which is why the ability to intervene early matters,\u201d says Eric Hughes, M.D., Ph.D., executive vice president of global research and development and chief medical officer at Teva. \u201cIf approved, BXCL501 could give adults living with schizophrenia or bipolar I or II disorder the ability to treat agitation at home, closer to the moment symptoms emerge and before they could become more difficult to manage.\u201d<\/p>\n
Rumi Therapeutics, a drug development company within Rumi Scientific Holdings, has entered an option to license agreement with Enthorin Therapeutics for RTX-7340 (ENT-7340), an investigational phosphodiesterase 2 (PDE2) inhibitor for Fragile X syndrome.3 Financial terms were not disclosed. <\/p>\n
Rumi describes the candidate as ready for an investigational new drug application and says the deal moves it toward clinical development.3<\/p>\n
Why target PDE2 in Fragile X syndrome?<\/p>\n
Fragile X syndrome is a genetic neurodevelopmental disorder caused by changes in the FMR1 gene that reduce or eliminate production of a protein important for brain development, and it is a leading inherited cause of intellectual disability.3 The program draws on preclinical Fragile X models, including human organoid studies from sister company Rumi Scientific. <\/p>\n
Rumi says PDE2A activity is increased in animal models and that inhibiting it has improved dendritic spine maturation, synaptic plasticity, and social and cognitive endpoints.3 An independent 2019 study in Cerebral Cortex found a similar pattern: PDE2A activity was elevated in the brains of Fmr1-knockout mice, and inhibiting it restored dendritic spine maturity and corrected social and communicative deficits in mouse and rat models.5<\/p>\n
What preclinical data support RTX-7340?<\/p>\n
Rumi says RTX-7340 studies in Fmr1-knockout mice showed correction of disease-associated electroencephalography abnormalities, which the company plans to use to select neurophysiological measures for clinical evaluation.3<\/p>\n
\u201cWe are pleased to partner with Rumi Therapeutics to advance RTX-7340 toward clinical evaluation in Fragile X syndrome. Rumi Scientific\u2019s human organoid capabilities complement the preclinical development work supporting the candidate and create an opportunity to deepen our understanding of its therapeutic potential. Together, we aim to translate that scientific foundation into a focused clinical development program,\u201d says J. Guy Breitenbucher, PhD, managing partner and co-founder of Enthorin Therapeutics.<\/p>\n
A clinician quoted in the release addresses the translational question. <\/p>\n
\u201cA central challenge in Fragile X drug development is connecting a treatment\u2019s effects on disease biology with outcomes that matter to patients. Combining human organoid research with neurophysiological measures creates an opportunity to build that connection more deliberately. A PDE2 program developed around this framework could help us evaluate both whether the drug affects relevant brain function and whether those effects translate into clinical benefit,\u201d says Craig Ericksson, director of the Fragile X Syndrome Research and Treatment Center at Cincinnati Children\u2019s Hospital.<\/p>\n
What remains unknown about RTX-7340?<\/p>\n
The evidence cited so far comes from animal models, and the release states that the candidate\u2019s human safety and efficacy have not been established. Because the arrangement is an option rather than a completed license, the release does not state the conditions or timeline for exercising it.3<\/p>\n
Biopharma and medtech deal reports for Q3 2026. J.P. Morgan. October 20, 2026. Accessed October 27, 2026. https:\/\/www.jpmorgan.com\/insights\/markets-and-economy\/outlook\/biopharma-medtech-deal-reports<\/a>Teva acquires worldwide rights to BXCL501, further expanding innovative neuroscience pipeline. News release. Teva Pharmaceuticals. October 27, 2026. Accessed October 27, 2026. https:\/\/www.tevapharm.com\/news-and-media\/latest-news\/teva-acquires-worldwide-rights-to-bxcl501-further-expanding-innovative-neuroscience-pipeline\/<\/a>Rumi Therapeutics announces licensing agreement with Enthorin Therapeutics to advance RTX-7340, an IND-ready PDE2 inhibitor, for Fragile X syndrome. News release. Business Wire. October 26, 2026. Accessed October 27, 2026. https:\/\/www.businesswire.com\/news\/home\/20261026087479\/en\/Rumi-Therapeutics-Announces-Licensing-Agreement-With-Enthorin-Therapeutics-to-Advance-RTX-7340-an-IND-Ready-PDE2-Inhibitor-for-Fragile-X-Syndrome<\/a>BioXcel Therapeutics, Inc. Form 10-Q for the quarterly period ended June 30, 2026. US Securities and Exchange Commission. Accessed October 27, 2026. https:\/\/www.sec.gov\/Archives\/edgar\/data\/0001720893\/000110465926095965\/btai-20260630x10q.htm<\/a>Maurin T, Melancia F, Jarjat M, et al. Involvement of phosphodiesterase 2A activity in the pathophysiology of fragile X syndrome. Cereb Cortex. 2019;29(8). doi:10.1093\/cercor\/bhy192 <\/p>\n","protected":false},"excerpt":{"rendered":"Why does at-home treatment of agitation matter? Teva, citing its own market research, says acute agitation affects 25%…\n","protected":false},"author":2,"featured_media":658790,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[42,43,40,38,41,39],"class_list":["post-658789","post","type-post","status-publish","format-standard","has-post-thumbnail","category-headlines","tag-headlines","tag-news","tag-top-news","tag-top-stories","tag-topnews","tag-topstories"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/658789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=658789"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/658789\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/658790"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=658789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=658789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=658789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}